MT
Curadev Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CRD3874-SI | Various Cancers | Phase 1 |
| STING Antagonist Program | Runaway Immune Responses (e.g., autoimmune) | Preclinical |
| TNIK Inhibitor (Compound 6) | Liver Fibrosis / Metabolic Disorders | Preclinical (IND candidate) |
| CLK/DYRK Dual Inhibitor (Compound 9) | Osteoarthritis | Preclinical (IND candidate) |
| Neuroinflammation Target ID | Neurodevelopmental/Neurodegenerative Disorders | Discovery |